Pipeline news
-
Marinus Pharmaceuticals Announces Pricing of Public Offering of Common Stock
12 December 2018
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (“Marinus” or the “Company”) announced the pricing of an underwritten public offering of 12,000,000 shares of common stock at a public offering price of $3.75 per share. The total public offering size is expected to be $45.0 million , before deducting the underwriting discounts and commissions and other offering expenses payable by the Company.
-
Marinus Pharmaceuticals Announces Public Offering of Common Stock
11 December 2018
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS), (“Marinus” or the “Company”) today announced that it intends to offer and sell 12,000,000 shares of its common stock in an underwritten public offering. All of the shares in the offering are to be sold by Marinus. Jefferies LLC and Leerink Partners LLC are acting as joint bookrunning managers for the offering. Marinus also expects to grant the underwriters a 30-day option to purchase up to an additional 1,800,000 shares of common stock.
-
Marinus Pharmaceuticals Announces Positive Ganaxolone Data in Women With Postpartum Depression
10 December 2018
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (“Marinus” or “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy, depression and other neuropsychiatric disorders, today announced positive results from its Phase 2 clinical trials evaluating ganaxolone intravenous (IV) (the Magnolia Study) and oral (the Amaryllis Study) in women with postpartum depression (PPD). Based on these results, the Company is advancing both studies into the next phase of development to evaluate IV and oral dose regimens.
-
04 December 2018
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that ganaxolone data from its Phase 2 clinical trial in pediatric genetic epilepsies, CDKL5 Deficiency Disorder (CDD) and PCDH19-related pediatric epilepsy (PCDH19 epilepsy) were presented at the American Epilepsy Society ( AES ) Annual Meeting in New Orleans on December 2 and 3, 2018.
-
09 November 2018
Atea Pharmaceuticals, Inc., a biopharmaceutical company engaged in the development of next-generation therapeutics for the treatment of hepatitis C and other single stranded RNA viral infections, today announced it will present positive data from its recently completed Phase IB/IIA trial of AT-527 in treatment-naïve HCV-infected patients, including HCV-infected patients with Child-Pugh A (CPA) cirrhosis. The data will be presented on November 10, 2018 at The Liver Meeting® 2018 sponsored by the American Association for the Study of Liver Diseases taking place in San Francisco, California.
-
Clearside Biomedical Announces Third Quarter 2018 Financial Results and Provides Corporate Update
08 November 2018
Clearside Biomedical, Inc. (NASDAQ: CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today reported financial results for the quarter ended September 30, 2018 and provided an update on its development programs.
-
05 November 2018
Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced it will provide an update on E2112, its NCI-sponsored, ECOG-ACRIN led pivotal trial of entinostat plus exemestane in hormone receptor positive, human epidermal growth factor receptor 2 negative (HR+, HER2-) breast cancer as well as its registration strategy for entinostat in combination with KEYTRUDA® (pembrolizumab) in patients with non-small cell lung cancer (NSCLC).
-
29 October 2018
Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that additional data from PEACHTREE, the company’s pivotal Phase 3 trial of XIPERE™ (formerly “suprachoroidal CLS-TA”) in patients with uveitic macular edema, were presented at the American Academy of Ophthalmology (“AAO”) 2018 Annual Meeting by Rahul N. Khurana , MD, Vitreoretinal Surgeon at Northern California Retina Vitreous Associates , Clinical Associate Professor in Ophthalmology at UCSF Medical Center , and a Principal Investigator for PEACHTREE.
-
29 October 2018
Epic Sciences, Inc. (Epic) and Genomic Health, Inc. (Nasdaq: GHDX) announced today that Palmetto GBA, a Medicare Administrative Contractor that assesses molecular diagnostic technologies, has issued a positive final local coverage determination (LCD) for the Oncotype DX® AR-V7 Nucleus Detect™ test. The final LCD recommends Medicare coverage for use of the test effective December 10, 2018, throughout the United States to help determine which patients with metastatic castrate resistant prostate cancer (mCRPC) may benefit from continued androgen receptor signaling inhibitor (ARSi) therapy, such as enzalutamide, abiraterone and apalutamide, as well as those who are resistant who may benefit from chemotherapy.
-
Marinus Pharmaceuticals Provides Business Update and Third Quarter 2018 Financial Results
29 October 2018
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business update on its clinical development activities and reported its financial results for the third quarter ended September 30, 2018.
